- Japan: 530000 people with side effects after receiving the 3rd dose of Pfizer COVID-19 vaccine
- The Lancet: COVID-19 pandemic will end in March?
- Austria becomes EU first country to make COVID-19 vaccine mandatory
- Moderna COVID-19 vaccine: Less breakthrough infections than Pfizer’s
- Viatris recalls Semglee insulin pens due to lack of label risk.
- Biomarkers and prospects for immunotherapy in hepatocellular carcinoma
Nature: Can Alzheimer’s disease can be predicted in future? Up to 5 years in advance!
Nature: Can Alzheimer’s disease can be predicted in future? The development of Alzheimer’s disease (usually caused by Alzheimer’s disease) is related to abnormal levels of dozens of proteins in the blood, which can be advanced by up to 5 years.
In order to promote the dissemination of science, Biocom has collected this article. If you want to request the original English text, please click! Request original text
A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health shows that the development of Alzheimer’s disease (usually caused by Alzheimer’s disease) is related to the blood The abnormal levels of dozens of proteins are related to the abnormal levels, and this abnormal level can appear up to five years in advance. In the past, people did not know that most of these proteins were related to dementia, which provided new targets for preventive treatment.
The discovery is based on a new analysis of blood samples from more than 10,000 middle-aged and elderly people-these samples were collected and stored in a large-scale study decades ago as part of an ongoing study. Researchers believe that abnormal levels of 38 proteins in the blood are related to a higher risk of Alzheimer’s disease within five years. Of these 38 proteins, 16 seem to be able to predict the risk of Alzheimer’s disease 20 years in advance.
Although most of these risk indicators may only be by-products of the slow disease process leading to Alzheimer’s, analysis pointed out that high levels of SVEP1 protein may be one of the reasons for the disease process.
The research was published in the journal Nature Aging on May 14.
“This is the most comprehensive analysis of its kind to date, and it reveals multiple biological pathways related to Alzheimer’s disease,” said Josef Coresh, senior author of the study. “Some of the proteins we discovered are just indicators of the possible occurrence of diseases, but some of them may be causally related. This is exciting because it increases the possibility that future treatments will target these proteins.”
It is estimated that more than 6 million Americans suffer from Alzheimer’s disease, the most common type of dementia, an irreversible fatal disease that causes loss of cognitive and physical function. Despite decades of in-depth research, there is currently no treatment that can slow the progression of the disease, let alone stop or reverse it. Scientists generally believe that the best time to treat Alzheimer’s disease is before the symptoms of dementia appear.
Before the advent of dementia, people’s assessment of the risk of Alzheimer’s disease was mainly focused on the two most obvious features of Alzheimer’s disease brain pathology: the clumping of amyloid (ie plaque) and Tau protein. Tangled. Scientists have proven that brain imaging of plaques, and the levels of amyloid or tau in blood or cerebrospinal fluid, have certain value in predicting the age of Alzheimer’s disease in advance.
But there are thousands of different proteins in human cells and blood, and the technology to measure many of these proteins in a single, small blood sample has made progress in recent years. Can a more comprehensive analysis using this technique reveal other signs of Alzheimer’s disease? This is the question Coresh and his colleagues are trying to answer in this new study.
The researchers’ preliminary analysis of blood samples collected from more than 4,800 late-middle-aged participants in the risk of atherosclerosis in 2011-13. In the community (ARIC) study, a large number of epidemiological studies on the risks related to heart disease The factors and results have been operating in four American communities since 1985. Researchers working with a laboratory technology company called SomaLogic used their recently developed SomaScan technology to record the levels of nearly 5,000 different proteins in stored ARIC samples.
Researchers analyzed the results and found that abnormal levels of 38 proteins were significantly associated with the risk of Alzheimer’s disease within five years after the blood draw.
Then, they used SomaScan to measure protein levels in more than 11,000 blood samples taken from ARIC participants between 1993 and 1995, much younger. They found that in the nearly 20 years from that blood draw to the follow-up clinical evaluation from 2011 to 2013, abnormal levels of 16 of the 38 previously identified proteins were related to the development of Alzheimer’s disease.
To validate these findings in different patient groups, the scientists reviewed the SomaScan results of blood samples collected in a study conducted in Iceland from 2002 to 2006. The study analyzed proteins, including 13 of the 16 proteins identified in the ARIC analysis. Of these 13 proteins, 6 were again associated with the risk of Alzheimer’s disease during a follow-up period of approximately 10 years.
In further statistical analysis, the researchers compared the identified proteins with past research data on Alzheimer’s genetic links. This contrast strongly suggests that one of the identified proteins, SVEP1, is not only an incidental marker of Alzheimer’s risk, but also involved in initiating or promoting the disease.
SVEP1 is a protein, and its normal function is still somewhat mysterious, although in a study published earlier this year, it is related to arteriosclerosis, which is the basis of heart attacks and strokes.
In this new study, other proteins associated with the risk of Alzheimer’s include several key immune proteins-which have been linked to the fact that Alzheimer’s disease is associated with abnormally strong immune activity in the brain for decades. The findings are consistent.
Researchers plan to continue to use SomaScan and other technologies to analyze the proteins in blood samples stored in long-term studies to determine the pathways that may cause Alzheimer’s disease-a new method for Alzheimer’s disease treatment Potential strategy.
Scientists have also been studying the relationship between protein levels in ARIC samples and other diseases, such as blood vessel-related diseases in the brain, heart, and kidneys.
(source:internet, reference only)